I keep on asking the question as to why a researcher would be testing a drug like LDN, that's been out in the market for a couple of decades, on that poor EAE mouse??!! We know that that EAE is not the same as human MS and there aren't any safety issues with naltrexone (used at 30 x the dosage with addicts) so what does Zagon hope to learn? Was this something that the NMSS insisted on in order to get this tiny grant?

It seems that going into human trials for a medication that thousands of MS patients are already using with very few problems is the path to go.

Harry